These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

167 related items for PubMed ID: 11904529

  • 1. Comparative efficacy between the glycoprotein IIb/IIIa antagonists roxifiban and orbofiban in inhibiting platelet responses in flow models of thrombosis.
    Mousa SA, Abulencia JP, McCarty OJ, Turner NA, Konstantopoulos K.
    J Cardiovasc Pharmacol; 2002 Apr; 39(4):552-60. PubMed ID: 11904529
    [Abstract] [Full Text] [Related]

  • 2. Effects of glycoprotein IIb/IIIa antagonists on platelet activation: development of a transfer method to mimic peak to trough receptor occupancy.
    Billheimer JT, He B, Spitz SM, Stern AM, Seiffert D.
    Thromb Res; 2002 Sep 15; 107(6):303-17. PubMed ID: 12565717
    [Abstract] [Full Text] [Related]

  • 3. Comparative analysis of various platelet glycoprotein IIb/IIIa antagonists on shear-induced platelet activation and adhesion.
    Wang X, Dorsam RT, Lauver A, Wang H, Barbera FA, Gibbs S, Varon D, Savion N, Friedman SM, Feuerstein GZ.
    J Pharmacol Exp Ther; 2002 Dec 15; 303(3):1114-20. PubMed ID: 12438534
    [Abstract] [Full Text] [Related]

  • 4. Comparative antiplatelet efficacy of a novel, nonpeptide GPIIb/IIIa antagonist (XV454) and abciximab (c7E3) in flow models of thrombosis.
    Abulencia JP, Tien N, McCarty OJ, Plymire D, Mousa SA, Konstantopoulos K.
    Arterioscler Thromb Vasc Biol; 2001 Jan 15; 21(1):149-56. PubMed ID: 11145947
    [Abstract] [Full Text] [Related]

  • 5. Comparative in vitro efficacy of different platelet glycoprotein IIb/IIIa antagonists on platelet-mediated clot strength induced by tissue factor with use of thromboelastography: differentiation among glycoprotein IIb/IIIa antagonists.
    Mousa SA, Khurana S, Forsythe MS.
    Arterioscler Thromb Vasc Biol; 2000 Apr 15; 20(4):1162-7. PubMed ID: 10764688
    [Abstract] [Full Text] [Related]

  • 6. Differential antiplatelet efficacy for various GPIIb/IIIa antagonists: role of plasma calcium levels.
    Mousa SA, Bozarth JM, Forsythe MS, Slee A.
    Cardiovasc Res; 2000 Sep 15; 47(4):819-26. PubMed ID: 10974231
    [Abstract] [Full Text] [Related]

  • 7. AlphaIIbbeta3 priming and clustering by orally active and intravenous integrin antagonists.
    Hantgan RR, Stahle MC, Connor JH, Connor RF, Mousa SA.
    J Thromb Haemost; 2007 Mar 15; 5(3):542-50. PubMed ID: 17166246
    [Abstract] [Full Text] [Related]

  • 8. Platelet GPIIb/IIIa binding characteristics of small molecule RGD mimetic: distinct binding profile for Roxifiban.
    Mousa SA, Bozarth JM, Naik UP, Slee A.
    Br J Pharmacol; 2001 Jun 15; 133(3):331-6. PubMed ID: 11375248
    [Abstract] [Full Text] [Related]

  • 9. Antiplatelet and antithrombotic effects of orbofiban, a new orally active GPIIb/IIIa antagonist, in guinea pigs.
    Ogawa T, Sugidachi A, Naganuma H, Asai F.
    Thromb Res; 2000 Mar 01; 97(5):307-15. PubMed ID: 10709906
    [Abstract] [Full Text] [Related]

  • 10. Effects of the glycoprotein IIb/IIIa antagonist Roxifiban on P-selectin expression, fibrinogen binding, and microaggregate formation in a phase I dose-finding study: no evidence for platelet activation during treatment with a glycoprotein IIb/IIIa antagonist.
    Seiffert D, Thomas BE, Bradley JD, Munzer DA, Tchinnes MA, Kornhauser DM, Cain VA, Hua TA, Feuerstein GZ, Martin DE, Stern AM.
    Platelets; 2003 May 01; 14(3):179-87. PubMed ID: 12850842
    [Abstract] [Full Text] [Related]

  • 11. Paradoxical inhibition of fibrinogen binding and potentiation of alpha-granule release by specific types of inhibitors of glycoprotein IIb-IIIa.
    Schneider DJ, Taatjes DJ, Sobel BE.
    Cardiovasc Res; 2000 Jan 14; 45(2):437-46. PubMed ID: 10728364
    [Abstract] [Full Text] [Related]

  • 12. Regulation of clot retraction by glycoprotein IIb/IIIa antagonists.
    Seiffert D, Pedicord DL, Kieras CJ, He B, Stern AM, Billheimer JT.
    Thromb Res; 2002 Nov 01; 108(2-3):181-9. PubMed ID: 12590956
    [Abstract] [Full Text] [Related]

  • 13. Differential effect of the GPIIb/IIIa antagonist orbofiban on human platelet aggregate formation in vitro.
    Racanelli AL, Gibbs SK, Zondlo SC, Seiffert DA, Friedman SM, Feuerstein GZ.
    Thromb Res; 2003 May 01; 110(2-3):99-105. PubMed ID: 12893024
    [Abstract] [Full Text] [Related]

  • 14. Antagonism of the GPIIb/IIIa receptor with the nonpeptidic molecule BIBU52: inhibition of platelet aggregation in vitro and antithrombotic efficacy in vivo.
    Guth BD, Seewaldt-Becker E, Himmelsbach F, Weisenberger H, Müller TH.
    J Cardiovasc Pharmacol; 1997 Aug 01; 30(2):261-72. PubMed ID: 9269956
    [Abstract] [Full Text] [Related]

  • 15. Using thrombelastography to determine the efficacy of the platelet glycoprotein IIb/IIIa antagonist, roxifiban, on platelet/fibrin-mediated clot dynamics in humans.
    Mousa SA, Bozarth JM, Seiffert D, Feuerstein GZ.
    Blood Coagul Fibrinolysis; 2005 Apr 01; 16(3):165-71. PubMed ID: 15795533
    [Abstract] [Full Text] [Related]

  • 16. In-vitro efficacy of different platelet glycoprotein IIb/IIIa antagonists and thrombolytics on platelet/fibrin-mediated clot dynamics in human whole blood using thrombelastography.
    Mousa SA.
    Blood Coagul Fibrinolysis; 2007 Jan 01; 18(1):55-60. PubMed ID: 17179828
    [Abstract] [Full Text] [Related]

  • 17. Ability of anti-glycoprotein IIb/IIIa agents to dissolve platelet thrombi formed on a collagen surface under blood flow conditions.
    Goto S, Tamura N, Ishida H.
    J Am Coll Cardiol; 2004 Jul 21; 44(2):316-23. PubMed ID: 15261925
    [Abstract] [Full Text] [Related]

  • 18. Comparative efficacy of different low-molecular-weight heparins (LMWHs) and drug interactions with LMWH: implications for management of vascular disorders.
    Mousa SA.
    Semin Thromb Hemost; 2000 Jul 21; 26 Suppl 1():39-46. PubMed ID: 11011805
    [Abstract] [Full Text] [Related]

  • 19. Effects of roxifiban on platelet aggregation and major receptor expression in patients with coronary artery disease for the Roxifiban Oral Compound Kinetics Evaluation Trial-I (ROCKET-I Platelet Substudy).
    Serebruany VL, Malinin AI, O'connor CM, Gurbel PA, Roxifiban Oral Compound Kinetics Evaluation Trial-I Platelet Substudy.
    Am Heart J; 2003 Jul 21; 146(1):91-8. PubMed ID: 12851613
    [Abstract] [Full Text] [Related]

  • 20. Orbofiban: an orally active GPIIb/IIIa platelet receptor antagonist.
    Nicholson NS, Abood NA, Panzer-Knodle SG, Frederick LG, Page JD, Salyers AK, Suleymanov OD, Szalony JA, Taite BB, Anders RJ.
    Med Res Rev; 2001 May 21; 21(3):211-26. PubMed ID: 11301411
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.